Back to top
more

Deciphera Pharmaceuticals (DCPH)

(Delayed Data from NSDQ)

$25.38 USD

25.38
1,940,699

0.00 (0.00%)

Updated May 3, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (80 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Vertex (VRTX) Beats on Q2 Earnings, Ups 2022 Sales Guidance

by Zacks Equity Research

Vertex Pharmaceuticals' (VRTX) Q2 earnings and sales beat estimates. The company increases its revenue guidance for 2022.

Deciphera (DCPH) Loss Narrows in Q2, Qinlock Drive Revenues

by Zacks Equity Research

Deciphera (DCPH) reports a narrower-than-expected loss in the second quarter of 2022 while revenues beat estimates. Shares rise.

Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of 7.69% and 7.56%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

BioMarin's (BMRN) Q2 Earnings Top, Voxzogo Drives Sales

by Zacks Equity Research

Biomarin Pharmaceutical's (BMRN) second-quarter earnings and sales beat estimates. BMRN slightly raises its sales guidance for the year.

Analysts Estimate BioMarin Pharmaceutical (BMRN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Does Deciphera Pharmaceuticals, Inc. (DCPH) Have the Potential to Rally 27% as Wall Street Analysts Expect?

by Zacks Equity Research

The consensus price target hints at a 26.9% upside potential for Deciphera Pharmaceuticals, Inc. (DCPH). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Will Deciphera Pharmaceuticals, Inc. (DCPH) Report Negative Q2 Earnings? What You Should Know

by Zacks Equity Research

Deciphera Pharmaceuticals, Inc. (DCPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is Deciphera Pharmaceuticals (DCPH) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Deciphera Pharmaceuticals, Inc. (DCPH) and Evolus, Inc. (EOLS) have performed compared to their sector so far this year.

Has Deciphera Pharmaceuticals (DCPH) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Deciphera Pharmaceuticals, Inc. (DCPH) and Eiger BioPharmaceuticals (EIGR) have performed compared to their sector so far this year.

Blueprint Medicines' (BPMC) Ayvakit Aids Growth Amid Rivalry

by Zacks Equity Research

Blueprint Medicines' (BPMC) lead drug, Ayvakit, approved to treat rare cancer and other rare diseases, has seen strong uptake since approval. However, stiff competition remains a concern.

Deciphera (DCPH) Up More Than 30% in Past 3 Months: Here's Why

by Zacks Equity Research

Deciphera's (DCPH) Qinlock, approved for treating advanced gastrointestinal stromal tumors, has seen strong uptake since its approval. The recent restructuring initiative is saving costs.

Deciphera Pharmaceuticals, Inc. (DCPH) Up 4.3% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Deciphera Pharmaceuticals, Inc. (DCPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Deciphera (DCPH) Down Despite Narrower-Than-Expected Q1 Loss

by Zacks Equity Research

Deciphera (DCPH) reports narrower-than-expected loss in the first quarter of 2022 while revenues beat estimates.

Puma Biotech (PBYI) Q1 Earnings Beat, Nerlynx Sales Fall Y/Y

by Zacks Equity Research

Puma Biotech (PBYI) Q1 loss narrows while sales come in line with estimates. PBYI's stock declines in the after-market trading session following the news.

    Vertex (VRTX) Q1 Earnings Lag, Sales Top, Expense View Tweaked

    by Zacks Equity Research

    Vertex Pharmaceuticals' (VRTX) earnings miss estimates while sales beat the same for the first quarter of 2022. The company maintains its revenue guidance for 2022.

      Amarin (AMRN) Q1 Earnings & Sales Hurt by Vascepa Generics

      by Zacks Equity Research

      Amarin's (AMRN) Vascepa sales decline year over year amid rising generic competition and COVID-related disruptions during the first quarter. The company's stock falls significantly on May 4.

      Clovis (CLVS) Q1 Loss Wider than Expected, Revenues Miss

      by Zacks Equity Research

      Clovis (CLVS) incurs wider-than-estimated loss for first-quarter 2022. Sales of the sole marketed drug Rubraca decline year over year due to COVID-19 impacts.

      Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q1 Loss, Tops Revenue Estimates

      by Zacks Equity Research

      Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of 4.76% and 7.47%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

      Why Axsome (AXSM) is Up 7% Despite Wider-Than-Expected Q1 Loss

      by Zacks Equity Research

      Axsome (AXSM) reports a slightly wider-than-estimated Q1 loss. It expects to receive FDA approval for its lead candidate AXS-05 by second-quarter 2022 to treat major depressive disorder.

      Can Deciphera Pharmaceuticals, Inc. (DCPH) Climb 79% to Reach the Level Wall Street Analysts Expect?

      by Zacks Equity Research

      The consensus price target hints at a 78.9% upside potential for Deciphera Pharmaceuticals, Inc. (DCPH). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

      AstraZeneca (AZN) Q1 Earnings and Revenues Beat Estimates

      by Zacks Equity Research

      AstraZeneca's (AZN) first-quarter results reflect a beat on both counts (revenues and earnings). AZN maintains its 2022 guidance.

      Emergent's (EBS) Q1 Earnings Miss, Revenues Beat Estimates

      by Zacks Equity Research

      Emergent's (EBS) first-quarter 2022 earnings miss estimates while sales beat the mark. EBS suspends its CDMO guidance for 2022 until it gets a better picture of the COVID-19 vaccine requirements.

      Repligen (RGEN) Q1 Earnings and Sales Beat Estimates, Stock Up

      by Zacks Equity Research

      Repligen (RGEN) reports encouraging first-quarter results with both sales and earnings beating estimates. RGEN also reduced its financial guidance for 2022

      BioMarin (BMRN) Q1 Earnings and Revenues Beat Estimates

      by Zacks Equity Research

      Biomarin Pharmaceutical's (BMRN) first-quarter earnings and sales beat estimates. BMRN also raises its financial guidance for 2022 Voxzogo sales by $10 million.

      Eli Lilly (LLY) Beats on Q1 Earnings, Ups Sales View, Stock Rises

      by Zacks Equity Research

      Eli Lilly (LLY) beats first-quarter estimates for both earnings and sales and ups its sales outlook for 2022. The stock rises in pre-market trading.